Alexandra Monastirli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra Monastirli has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Dionysios Tsambaos
Department of Dermatology, School of Medicine, University of Patras, Greece Center for Dermatologic Diseases, Limassol
6 shared publications - Efstathia Pasmatzi
Department of Dermatology-Venereology, School of Medicine, University of Patras, 26504 Patras, Greece
5 shared publications - George Badavanis
Center for Dermatologic Diseases, Limassol, Cyprus
5 shared publications Nikiforos Kapranos
Laboratory for Molecular Histopathology, Athens
3 shared publications- Sophia Georgiou
Department of Dermatology-Venereology, School of Medicine, University of Patras, 26504 Patras, Greece
2 shared publications Alexandros Sagriotis
Departments of 1 Dermatology and
1 shared publication
Latest Publications
- Open Access
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (2)
Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata
Erythema nodosum (EN) is a form of septal panniculitis, which is believed to represent a delayed hypersensitivity reaction activated by infectious agents, drugs, granulomatous and autoimmune diseases, pregnancy, and malignancies. There are only four reported cases of EN during oral isotretinoin therapy to our knowledge, all of them occurring in patients with severe acne. Since acne itself can trigger EN, the question as to whether there is indeed a causative relationship between isotretinoin and EN in the reported cases remains to be elucidated. We present herein a 20-year-old woman with multiple vulvar condylomata acuminata who developed EN two weeks after onset of oral isotretinoin therapy. To the best of our knowledge, this is the first report of EN occurring during isotretinoin treatment in a patient without acne and strongly indicates that the pathogenesis of EN can be directly related to the biological actions of isotretinoin. Erythema nodosum should be regarded as a rare side effect of oral isotretinoin therapy, regardless of the underlying disease. Physicians should be aware of this rare side effect.
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (2)
Open AccessErythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata
Erythema nodosum (EN) is a form of septal panniculitis, which is believed to represent a delayed hypersensitivity reaction activated by infectious agents, drugs, granulomatous and autoimmune diseases, pregnancy, and malignancies. There are only four reported cases of EN during oral isotretinoin therapy to our knowledge, all of them occurring in patients with severe acne. Since acne itself can trigger EN, the question as to whether there is indeed a causative relationship between isotretinoin and EN in the reported cases remains to be elucidated. We present herein a 20-year-old woman with multiple vulvar condylomata acuminata who developed EN two weeks after onset of oral isotretinoin therapy. To the best of our knowledge, this is the first report of EN occurring during isotretinoin treatment in a patient without acne and strongly indicates that the pathogenesis of EN can be directly related to the biological actions of isotretinoin. Erythema nodosum should be regarded as a rare side effect of oral isotretinoin therapy, regardless of the underlying disease. Physicians should be aware of this rare side effect.
- Open Access
- 30 December 2019
- Published by Association of Slovenian Dermatovenerologists in Acta Dermatovenerologica Alpina Pannonica et Adriatica
- Vol. 28 (4) , 173-176
Pemphigus vulgaris possibly associated with application of a tissue expander in a patient with Crohn’s disease and primary sclerosing cholangitis
- 30 December 2019
- Published by Association of Slovenian Dermatovenerologists in Acta Dermatovenerologica Alpina Pannonica et Adriatica
- Vol. 28 (4) , 173-176
Open AccessPemphigus vulgaris possibly associated with application of a tissue expander in a patient with Crohn’s disease and primary sclerosing cholangitis
- Open Access
- 1 May 2019
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 94 (3) , 348-354
Galectin 3: an extraordinary multifunctional protein in dermatology. Current knowledge and perspectives
Galectin 3 is a unique ~31 kDa protein that recognizes the N-acetyl-lactosamine structure of several glycoconjugates. It mainly occurs in epithelial and myeloid cells, but is also found in a variety of human cell types. In view of the crucial role played by galectin 3 in the regulation of cellular processes of essential importance and in the pathogenetic mechanisms of diverse disorders, it is not surprising that, particularly in the last three decades, the attention of the scientific community has been increasingly drawn to this extraordinary and multifunctional galectin. In this paper the authors summarize current knowledge on the expression of galectin 3 in normal and diseased human skin, its implications in the pathogenesis, diagnosis and prognosis of cutaneous disorders, and the perspectives of a novel approach to the treatment of the latter using galectin 3 or its inhibitors/antagonists.
- 1 May 2019
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 94 (3) , 348-354
Open AccessGalectin 3: an extraordinary multifunctional protein in dermatology. Current knowledge and perspectives
Galectin 3 is a unique ~31 kDa protein that recognizes the N-acetyl-lactosamine structure of several glycoconjugates. It mainly occurs in epithelial and myeloid cells, but is also found in a variety of human cell types. In view of the crucial role played by galectin 3 in the regulation of cellular processes of essential importance and in the pathogenetic mechanisms of diverse disorders, it is not surprising that, particularly in the last three decades, the attention of the scientific community has been increasingly drawn to this extraordinary and multifunctional galectin. In this paper the authors summarize current knowledge on the expression of galectin 3 in normal and diseased human skin, its implications in the pathogenesis, diagnosis and prognosis of cutaneous disorders, and the perspectives of a novel approach to the treatment of the latter using galectin 3 or its inhibitors/antagonists.
- Open Access
- 1 January 2017
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 23 (11)
Classic form of eosinophilic pustular folliculitis in an immunocompetent girl: rapid and complete resolution after low-dose oral indomethacin treatment
Eosinophilic pustular folliculitis (EPF) is a rare noninfectious pruritic dermatosis, first described by Ise and Ofuji in 1965. We report the case of a 15-year oldimmunocompetent girl that presented with a widespread papulopustular eruption four days after her arrival in Japan. The clinical diagnosis of the classicform of EPF was confirmed by histological examination of the lesional skin that revealed an intense, mainly eosinophilic, dermal infiltrate within and aroundpilosebaceous units. Oral administration of lowdose indomethacin (25 mg/day) led to a complete resolution of the eruption within 6 weeks without causing any side effects. The patient is presently completing a 15-month follow-up and remains free ofrelapses. To the best of our knowledge, it is the first time that low-dose oral indomethacin is reported to be capable of causing a rapid and complete resolutionof the classic form of EPF.
- 1 January 2017
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 23 (11)
Open AccessClassic form of eosinophilic pustular folliculitis in an immunocompetent girl: rapid and complete resolution after low-dose oral indomethacin treatment
Eosinophilic pustular folliculitis (EPF) is a rare noninfectious pruritic dermatosis, first described by Ise and Ofuji in 1965. We report the case of a 15-year oldimmunocompetent girl that presented with a widespread papulopustular eruption four days after her arrival in Japan. The clinical diagnosis of the classicform of EPF was confirmed by histological examination of the lesional skin that revealed an intense, mainly eosinophilic, dermal infiltrate within and aroundpilosebaceous units. Oral administration of lowdose indomethacin (25 mg/day) led to a complete resolution of the eruption within 6 weeks without causing any side effects. The patient is presently completing a 15-month follow-up and remains free ofrelapses. To the best of our knowledge, it is the first time that low-dose oral indomethacin is reported to be capable of causing a rapid and complete resolutionof the classic form of EPF.
- Open Access
- 19 December 2008
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 89 (2) , 134-139
Topical Application of Imiquimod Induces Alterations in Peripheral Blood Lymphocytes in Healthy Individuals*
The aim of this study was to determine whether imiquimod, a Toll-like receptor-7/8 agonist, in addition to its well-known topical action on the cutaneous immune response, might also induce alterations in the peripheral blood lymphocytes. A 62.5 mg quantity of imiquimod (5% cream) was applied topically under occlusion once daily every second day for 3 weeks to the skin of 10 healthy volunteers, age range 30–57 years. Ten sex- and age-matched healthy controls applied corresponding quantities of the vehicle under occlusion. Before, and one and 3 weeks after the start of treatment, peripheral blood lymphocyte subpopulations were measured by flow cytometry. Statistically significant alterations in the percentage or absolute numbers of peripheral blood lymphocyte subpopulations were found in the imiquimod-treated group compared with the control group. These alterations indicate for the first time that topical application of imiquimod induces alterations in peripheral blood lympho cyte subsets in healthy individuals, which may be of importance in the immunotherapy of neoplastic and infectious disorders and should be taken into careful consideration in patients who are treated with imiquimod.
- 19 December 2008
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 89 (2) , 134-139
Open AccessTopical Application of Imiquimod Induces Alterations in Peripheral Blood Lymphocytes in Healthy Individuals*
The aim of this study was to determine whether imiquimod, a Toll-like receptor-7/8 agonist, in addition to its well-known topical action on the cutaneous immune response, might also induce alterations in the peripheral blood lymphocytes. A 62.5 mg quantity of imiquimod (5% cream) was applied topically under occlusion once daily every second day for 3 weeks to the skin of 10 healthy volunteers, age range 30–57 years. Ten sex- and age-matched healthy controls applied corresponding quantities of the vehicle under occlusion. Before, and one and 3 weeks after the start of treatment, peripheral blood lymphocyte subpopulations were measured by flow cytometry. Statistically significant alterations in the percentage or absolute numbers of peripheral blood lymphocyte subpopulations were found in the imiquimod-treated group compared with the control group. These alterations indicate for the first time that topical application of imiquimod induces alterations in peripheral blood lympho cyte subsets in healthy individuals, which may be of importance in the immunotherapy of neoplastic and infectious disorders and should be taken into careful consideration in patients who are treated with imiquimod.
- 1 January 2006
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 17 (1) , 6-8
Short‐term oral isotretinoin therapy does not cause clinical or subclinical peripheral neuropathy
Subclinical neurophysiologic abnormalities mainly suggestive of sensory fibers dysfunction were observed in some patients after 1 and 3 months of treatment with oral acitretin. Moreover, two cases of peripheral sensory neuropathy and one of sensorimotor polyneuropathy were observed after short-term oral administration of this compound. The objective of this prospective study was to investigate whether short-term treatment with oral isotretinoin can also affect peripheral nerve function. Serial neurologic and neurophysiologic examinations were performed on 18 young patients with severe nodulocystic acne prior to and 1 and 3 months after the onset of oral isotretinoin treatment (1 mg/kg per day). Clinical neurologic examination before and under treatment disclosed no abnormalities in any of the patients. There were no significant differences between the pre- and post-treatment neurophysiologic parameters. Furthermore, evaluation of the serial neurophysiologic measurements in each patient separately under oral isotretinoin treatment revealed no changes fulfilling the criteria of abnormality. Short-term administration of oral isotretinoin in young patients does not cause clinical or subclinical neuropathy.
- 1 January 2006
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 17 (1) , 6-8
Short‐term oral isotretinoin therapy does not cause clinical or subclinical peripheral neuropathy
Subclinical neurophysiologic abnormalities mainly suggestive of sensory fibers dysfunction were observed in some patients after 1 and 3 months of treatment with oral acitretin. Moreover, two cases of peripheral sensory neuropathy and one of sensorimotor polyneuropathy were observed after short-term oral administration of this compound. The objective of this prospective study was to investigate whether short-term treatment with oral isotretinoin can also affect peripheral nerve function. Serial neurologic and neurophysiologic examinations were performed on 18 young patients with severe nodulocystic acne prior to and 1 and 3 months after the onset of oral isotretinoin treatment (1 mg/kg per day). Clinical neurologic examination before and under treatment disclosed no abnormalities in any of the patients. There were no significant differences between the pre- and post-treatment neurophysiologic parameters. Furthermore, evaluation of the serial neurophysiologic measurements in each patient separately under oral isotretinoin treatment revealed no changes fulfilling the criteria of abnormality. Short-term administration of oral isotretinoin in young patients does not cause clinical or subclinical neuropathy.